AACR Annual Meeting 2017: The Patient Perspective

The American Association for Cancer Research (AACR) Annual Meeting 2017 brought some of the world’s greatest scientific minds to Washington, D.C., to address research challenges in cancer. But significant findings also came from cancer patient advocates and survivors who attended the meeting.

Read More

Congressman Advocates for Increased Funding for Cancer Research and Prevention

Last month, U.S. Rep. Donald Payne Jr. (D-New Jersey), led a roundtable discussion at University Hospital in Newark, New Jersey, titled “Cancer Research Today: Innovation, Progress and Promise.” Payne shared his family’s history as part of an effort to increase awareness about colorectal cancer screening.

Read More

AACR Annual Meeting 2017: Challenging the Dogma of Treating IDH-mutant Cancers With IDH Inhibitors

Two studies presented at the AACR Annual Meeting 2017 showed that tumors that have mutations in the proteins isocitrate dehydrogenase-1 or -2 (IDH1/2) exhibited features similar to that of BRCA-mutant tumors and are, therefore, more likely to respond better to PARP inhibitors than to IDH inhibitors.

Read More

AACR Annual Meeting 2017: Most Merkel Cell Carcinoma Responses to the Newly FDA-Approved Avelumab Expected to Last More than a Year

T cells and antibodies

On March 23, the U.S. Food and Drug Administration announced the first-ever approval of a treatment for patients with a rare, aggressive form of skin cancer called Merkel cell carcinoma. The treatment, the immunotherapeutic avelumab (Bavencio), was approved based on data from the JAVELIN Merkel 200 phase II clinical trial.

Read More

AACR Annual Meeting 2017: If You Can’t Drug It, Degrade It – A Protein Degradation Technology to Tackle Undruggable Oncoproteins

Finding a way to therapeutically target the so-called “undruggable” cancer proteins has long been a holy grail of researchers in the field of oncology drug development.

Read More

“No Time to Stop the Momentum”

Former Vice President Joe Biden returned to the stage at the American Association for Cancer Research (AACR) Annual Meeting on Monday, sounding a battle cry to continue the momentum for cancer research that began when he launched the National Cancer Moonshot Initiative in 2016.

Read More

AACR Annual Meeting 2017: Immunotherapy Provides Long-lasting Responses to Certain Cancer Types

Now that a plethora of clinical trials have established positive responses from immunotherapies—immune checkpoint inhibitors, in particular—in patients with a variety of cancer types, one of the logical next questions is, are the responses durable?

Read More

FDA Approves New PARP Inhibitor for Ovarian Cancer

Earlier this week, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic niraparib (Zejula) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers that are responding to platinum-based chemotherapy.

Read More